Indonesian prosecutors seek up to 10 years’ jail for alleged baby trafficking ring linked to Singapore

Indonesian prosecutors are seeking up to 10 years in prison for alleged members of a cross-border baby trafficking ring ...

Indonesian prosecutors seek up to 10 years for alleged baby trafficking ring linked to Singapore

Indonesian prosecutors are seeking up to 10 years in prison for alleged members of a cross-border baby trafficking ring ...
CNA

Trafficking fears and red flags: Singapore couples caught up in botched overseas adoption attempts

A Singapore couple told CNA that they were handed a baby in a restaurant in Malaysia and told to take her and go, without any ...
AsiaNews

Trafficking between Indonesia and Singapore with newborns sold abroad

A case that began after authorities rescued six newborns bound for the city-state has put the spotlight on a widespread ...
CNBC

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Eli Lilly's Jacob Van Naarden says Lilly is using the financial strength from its GLP-1 drugs like Mounjaro and Zepbound to fund its new dealmaking strategy. Van Naarden recently became Lilly's head ...
FierceBiotech

Lilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

AlzeCure Pharma CEO Martin Jonsson and CSO Johan Sandin. (AlzeCure Pharma) Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease ...
FiercePharma

Lilly, Boehringer to slash at least $1B each from planned investments in Germany

In response to a planned healthcare reform initiative in Germany, which would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the ...
FierceBiotech

ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Eli Lilly is deepening the case for its asset to help a wide range of patients in need of chronic weight management. (Fraiser Kansteiner) Even as Zepbound and Mounjaro fire on all cylinders and ...
The Motley Fool

Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years

It would put it ahead of Eli Lilly (LLY 2.34%), the pharmaceutical giant that has become the leader in obesity drugs. That's not to knock Eli Lilly, which happens to be a behemoth in its own right, ...
FiercePharma

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

Positive data on Eli Lilly's obesity and diabetes candidate retatrutide highlighted the Amercian Diabetes Association Scientific Sessions last weekend in New Orleans. () It’s a sign of the times that ...
Reuters

Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

June 8 (Reuters) - Eli Lilly (LLY.N), opens new tab shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it ...
Reuters

Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs

June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly (LLY.N), opens new tab, worth up to $1.9 billion, ...